AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25344024 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-depth footwear
Number of subjects: 59
Study 22305197 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral thiamine hydrochloride
Number of subjects: 0
Study 22305197 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral thiamine hydrochloride
Number of subjects: 0
Study 22305197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg oral thiamine hydrochloride
Number of subjects: 0
Study 22305197 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20663072 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative cardiac output measurement using inert gas rebreathing (IGR)
Number of subjects: 24
Study 17621459 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV/r)
Number of subjects: 4000
Study 17621459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Number of subjects: 4000
Study 17621459 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 4000
Study 17621459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF)
Number of subjects: 4000
Study 17621459 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20)
Number of subjects: 4000
Study 15866997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 483
Study 15866997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 483
Study 15866997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 10999733 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 200 microg three times daily
Number of subjects: 84
Study 10999733 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 500 microg three times daily
Number of subjects: 84
Study 10999733 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil with or without leucovorin
Number of subjects: 84
Study 9126802 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 600 mg per day
Number of subjects: 60
Study 9126802 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 60
Study 1493839 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 16
Study 1493839 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 16
Study 1493839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3981952 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative chloride titrator
Number of subjects: 0
Study 3981952 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative chloride titrator
Number of subjects: 0
Study 3981952 — intervention group
Group type: COMPARATOR
Intervention: Control (common antihypertensive medications)
Number of subjects: 0
Study 3981952 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional chloride intake (potassium chloride)
Number of subjects: 0
Study 30743107 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2α (AL mares)
Number of subjects: 7
Study 30743107 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control mares)
Number of subjects: 7
Study 29421015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor
Number of subjects: 1856
Study 29421015 — intervention group
Group type: COMPARATOR
Intervention: In-hospital ticagrelor
Number of subjects: 1856
Study 26390014 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Specificity Training (MeST)
Number of subjects: 0
Study 26390014 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 23945716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried sea buckthorn berries (SBs)
Number of subjects: 80
Study 23945716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBo)
Number of subjects: 80
Study 23945716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn phenolics ethanol extract mixed with maltodextrin (SBe+MD)
Number of subjects: 80
Study 23945716 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen bilberries
Number of subjects: 80
Study 20647562 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté PES
Number of subjects: 60
Study 20647562 — intervention group
Group type: EXPERIMENTAL
Intervention: JACTAX HD (9.2 microg each of polymer and paclitaxel per 16-mm stent)
Number of subjects: 60
Study 20647562 — intervention group
Group type: EXPERIMENTAL
Intervention: JACTAX LD (5 microg each of polymer and paclitaxel)
Number of subjects: 60
Study 20647562 — intervention group
Group type: EXPERIMENTAL
Intervention: JACTAX HD
Number of subjects: 60
Study 20647562 — intervention group
Group type: EXPERIMENTAL
Intervention: JACTAX LD
Number of subjects: 60
Study 18230234 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (20-minute sessions for 4 weeks)
Number of subjects: 88
Study 18230234 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing (20-minute sessions for 4 weeks)
Number of subjects: 88
Study 16633921 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 2000
Study 16633921 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2000
Study 13678973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg at labour onset and 2mg/kg for babies within 72 h of birth)
Number of subjects: 645
Study 13678973 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (600 mg orally at labour onset and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily for babies for 7 days)
Number of subjects: 645
Study 11075769 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide plus cyclosporin (50 mg/kg daily for 4 days)
Number of subjects: 31
Study 11075769 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression with ATG plus cyclosporin (40 mg/kg daily for 4 days)
Number of subjects: 31
Study 11075769 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 31
Study 8883753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atad Ripener Device
Number of subjects: 114
Study 8883753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 intracervical gel (0.5 mg)
Number of subjects: 114
Study 8883753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 intravaginal pessary (3 mg)
Number of subjects: 114
Study 1422319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day
Number of subjects: 16
Study 1422319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone 1200 mg/day
Number of subjects: 16
Study 1422319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone 1200/600 mg/day sequence
Number of subjects: 16
Study 3081211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active mobilisation
Number of subjects: 61
Study 3081211 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (rest and immobilisation with a soft cervical collar)
Number of subjects: 61
Study 29411360 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive rehabilitation (CR) therapy consisting of eight 2-hour sessions over a 4-week period.
Number of subjects: 34
Study 29411360 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive rehabilitation (CR) therapy
Number of subjects: 34
Study 29411360 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-therapeutic group sessions)
Number of subjects: 34
Study 27173861 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned single zotarolimus-eluting stent strategy
Number of subjects: 450
Study 27173861 — intervention group
Group type: COMPARATOR
Intervention: Planned dual zotarolimus-eluting stent strategy
Number of subjects: 450
Study 24589784 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse Acetabular Ligament (TAL) group
Number of subjects: 80
Study 24589784 — intervention group
Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 80
Study 22785608 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months
Number of subjects: 119
Study 20163570 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous smoking
Number of subjects: 78
Study 20163570 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation with transdermal nicotine patch
Number of subjects: 78
Study 20163570 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (control)
Number of subjects: 78
Study 18315976 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightbearing CT scan
Number of subjects: 48
Study 19552488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 2.5 mg
Number of subjects: 307
Study 19552488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 5 mg
Number of subjects: 307
Study 19552488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 10 mg
Number of subjects: 307
Study 19552488 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg
Number of subjects: 307
Study 19552488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 16314787 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-CsA-ST (triple therapy)
Number of subjects: 430
Study 16314787 — intervention group
Group type: COMPARATOR
Intervention: SRL-ST (sirolimus and steroids only)
Number of subjects: 430
Study 11421499 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen therapy
Number of subjects: 5
Study 11421499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 5
Study 11421499 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal oxygen therapy
Number of subjects: 5
Study 11421499 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy
Number of subjects: 5
Study 9469531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 mg/ml morphine and 3 mg/ml ketorolac
Number of subjects: 42
Study 9469531 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 42
Study 9469531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of half-doses of morphine and ketorolac
Number of subjects: 42
Study 8203838 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin plus roxithromycin (150 mg twice daily)
Number of subjects: 131
Study 8203838 — intervention group
Group type: COMPARATOR
Intervention: ofloxacin alone
Number of subjects: 131
Study 3441016 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 20
Study 3441016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12225330 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin (combination therapy)
Number of subjects: 41
Study 12225330 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (monotherapy)
Number of subjects: 41
Study 29310619 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive scheme for breastfeeding (vouchers)
Number of subjects: 35
Study 27769840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step orthosis
Number of subjects: 44
Study 27769840 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthosis
Number of subjects: 44
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) preventive therapy
Number of subjects: 31
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylisoniazid (AcINH) detection
Number of subjects: 31
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: Arkansas test at 24 h
Number of subjects: 31
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: Arkansas test at 48 h
Number of subjects: 31
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: Arkansas test at 72 h
Number of subjects: 31
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: INH or AcINH detection at 24 h
Number of subjects: 31
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: INH or AcINH detection at 48 h
Number of subjects: 31
Study 24903787 — intervention group
Group type: EXPERIMENTAL
Intervention: INH or AcINH detection at 72 h
Number of subjects: 31
Study 22740380 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 0
Study 22740380 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 0
Study 22740380 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 20338901 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Quit Attempt (PQA)
Number of subjects: 750
Study 20338901 — intervention group
Group type: EXPERIMENTAL
Intervention: PQA plus Nicotine Replacement Therapy (NRT) sampling
Number of subjects: 750
Study 18356837 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day sibutramine for 5 days
Number of subjects: 20
Study 18356837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15986749 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery to create a pseudomeningomyelocele (artificial CSF reservoir)
Number of subjects: 58
Study 15986749 — intervention group
Group type: COMPARATOR
Intervention: Shunt implantation
Number of subjects: 58
Study 12609786 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergised-pyrethrins thermo-labile foam (F)
Number of subjects: 40
Study 12609786 — intervention group
Group type: COMPARATOR
Intervention: Permethrin 5% cream (P)
Number of subjects: 40
Study 11783169 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianlong Capsule (XLC)
Number of subjects: 46
Study 11783169 — intervention group
Group type: COMPARATOR
Intervention: Hydergine (Control)
Number of subjects: 46
Study 7575756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 40
Study 7575756 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 40
Study 1780723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infraorbital nerve block (1-1.5 ml) with 1:200,000 epinephrine
Number of subjects: 60
Study 1780723 — intervention group
Group type: COMPARATOR
Intervention: Saline injected into the vicinity of the infraorbital foramina (1-1.5 ml)
Number of subjects: 60
Study 1780723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infraorbital nerve block
Number of subjects: 60
Study 1780723 — intervention group
Group type: COMPARATOR
Intervention: Saline injected into the vicinity of the infraorbital foramina
Number of subjects: 60
Study 1780723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 60
Study 7023798 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (COP)
Number of subjects: 180
Study 7023798 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 180
Study 31402389 — intervention group
Group type: EXPERIMENTAL
Intervention: In-reach rehabilitation in addition to usual ward therapy (n=29)
Number of subjects: 62
Study 31402389 — intervention group
Group type: COMPARATOR
Intervention: Usual ward therapy (n=33)
Number of subjects: 62
Study 30242334 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Valproic Acid
Number of subjects: 0
Study 30242334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27448554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 27448554 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28
Study 25572630 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release calcifediol (30, 60, or 90 µg daily for six weeks)
Number of subjects: 78
Study 25572630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 22885021 — intervention group
Group type: COMPARATOR
Intervention: Control diet (C) consisting of 90% dehydrated lucerne and 10% wheat bran
Number of subjects: 36
Study 22885021 — intervention group
Group type: COMPARATOR
Intervention: C with 6% of oil blend (CO)
Number of subjects: 36
Study 22885021 — intervention group
Group type: EXPERIMENTAL
Intervention: C with 2.5% of grape seed extract (GS)
Number of subjects: 36
Study 22885021 — intervention group
Group type: EXPERIMENTAL
Intervention: GS with 6% of oil blend (GSO)
Number of subjects: 36
Study 22885021 — intervention group
Group type: EXPERIMENTAL
Intervention: C with 25% of Cistus ladanifer (CL)
Number of subjects: 36
Study 22885021 — intervention group
Group type: EXPERIMENTAL
Intervention: CL with 6% of oil blend (CLO)
Number of subjects: 36
Study 19910359 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) as an adjunct therapy
Number of subjects: 9
Study 19910359 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS with narcotic analgesics
Number of subjects: 9
Study 19910359 — intervention group
Group type: COMPARATOR
Intervention: TENS alone
Number of subjects: 9
Study 19910359 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS as an adjunct to other medications
Number of subjects: 9
Study 19910359 — intervention group
Group type: COMPARATOR
Intervention: TENS as sole pain-control treatment
Number of subjects: 9
Study 18602287 — intervention group
Group type: EXPERIMENTAL
Intervention: Night guard intervention (1.5‐mm‐thick ethylene vinyl acetate sheet)
Number of subjects: 0
Study 18602287 — intervention group
Group type: EXPERIMENTAL
Intervention: Night guard intervention
Number of subjects: 0
Study 15751668 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced prime volume (RPV)
Number of subjects: 222
Study 15751668 — intervention group
Group type: COMPARATOR
Intervention: Normal prime volume (NPV)
Number of subjects: 222
Study 15558302 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback conditions (individual, groups, or supervisors)
Number of subjects: 36
Study 15558302 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to supervisors
Number of subjects: 36
Study 15558302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 36
Study 10962112 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS patients (n=10)
Number of subjects: 30
Study 10962112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy patients (n=10)
Number of subjects: 30
Study 10962112 — intervention group
Group type: COMPARATOR
Intervention: Healthy HIV seronegative controls (n=10)
Number of subjects: 30
Study 9365969 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg.kg‐1 propacetamol (15 mg.kg‐1 acetaminophen)
Number of subjects: 87
Study 9365969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 87
Study 1411329 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized maintenance antipsychotic medication for at least 1 year
Number of subjects: 0
Study 3893694 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intravenously (30 mg/m2)
Number of subjects: 6
Study 3893694 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered orally (30 mg/m2)
Number of subjects: 6
Study 3893694 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intramuscularly (30 mg/m2)
Number of subjects: 6
Study 31232371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 0
Study 31232371 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 0
Study 29341850 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (monthly self-management education and quarterly medication management facilitation)
Number of subjects: 182
Study 27502820 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure for five days along with standard medications
Number of subjects: 48
Study 27502820 — intervention group
Group type: COMPARATOR
Intervention: Standard medications only
Number of subjects: 48
Study 24588854 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous human choriogonadotropin alfa followed by intravenous erythropoietin (4000-20,000 IU/dose)
Number of subjects: 96
Study 24588854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24588854 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment cohorts (human choriogonadotropin alfa and erythropoietin)
Number of subjects: 96
Study 22404250 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step technique (first treating only reticular veins with a single injection at the base of each cluster of telangiectasias, then successively injecting all remaining telangiectasias a few minutes later)
Number of subjects: 53
Study 22404250 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (successive injections of chromated glycerin mixed with one‐third lidocaine‐epinephrine 1%)
Number of subjects: 53
Study 19646775 — intervention group
Group type: EXPERIMENTAL
Intervention: Allelic imbalance in sputum and plasma samples
Number of subjects: 98
Study 19646775 — intervention group
Group type: EXPERIMENTAL
Intervention: Allelic imbalance
Number of subjects: 98
Study 19646775 — intervention group
Group type: EXPERIMENTAL
Intervention: LOH, K-ras mutations, and high levels of free plasma DNA (>5ng/ml plasma)
Number of subjects: 98
Study 19278086 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% KNO3 gel-to-foam dentifrice, brushed twice daily for either 45 seconds or two minutes for eight weeks, followed by regular dentifrice for four weeks.
Number of subjects: 141
Study 15641938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients (HD)
Number of subjects: 21
Study 15641938 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 21
Study 15641938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients with ischemic heart disease (IHD)
Number of subjects: 21
Study 15641938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients without ischemic heart disease (IHD)
Number of subjects: 21
Study 15641938 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid IMT
Number of subjects: 21
Study 12211491 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + M (scaling and root planing plus subgingival application of minocycline microspheres)
Number of subjects: 48
Study 12211491 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + M
Number of subjects: 48
Study 12211491 — intervention group
Group type: COMPARATOR
Intervention: SRP + V (scaling and root planing plus subgingival application of vehicle control)
Number of subjects: 48